58 LeventalK
[5] [8] Versus insulin , GLP-1 receptor agonists generally cause less hypoglycaemia and promote weight loss rather than weight gain
Tashiro K, Kaida Y, Yamagishi SI, Tanaka H, Yokoro M, Yano J, Sakai K, Kurokawa Y, Taguchi K, Nakayama Y, et al
However, newer medications target multiple metabolic hormones: GLP-1 drugs (single-hormone): semaglutide medications like Wegovy and Ozempic Dual-agonist drugs: tirzepatide medications like Mounjaro and Zepbound (target GLP-1 and GIP receptors) Triple-agonist drugs: retatrutide (targets GLP-1, GIP and glucagon receptors) Researchers believe stimulating multiple hormone pathways may produce stronger effects on appetite, metabolism and energy expenditure
Now, for the deeper 'why.' It all comes down to chemistry